AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)

AccuStem Sciences, Inc. announced the execution of a pilot study agreement with NSABP to evaluate StemPrintER in a subset of patients from the B-32 cohort. The StemPrintER test interrogates 20 genes to stratify patients with early stage breast cancer according to their recurrence risk.